NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that GE HealthCare Technologies Inc. (Nasdaq: GEHC), will become a component of the Nasdaq-100 Index® (Nasdaq: NDX), the Nasdaq-100 Equal Weighted Index (Nasdaq: NDXE), and the Nasdaq-100 Ex-Tech Sector Index (Nasdaq: NDXX) prior to market open on Wednesday, June 7, 2023. GE HealthCare Technologies Inc. will replace Fiserv, Inc. (Nasdaq: FISV) in the Nasdaq-100 Index®, the Nasdaq-100 Equal Weighted Index, and the Nasdaq-100 Ex-Tech Sector Index. Fiserv, Inc. will also be removed from the Nasdaq-100 ESG Index (Nasdaq: NDXESG) prior to market open on Wednesday, June 7, 2023.
For more information about the company, go to https://www.gehealthcare.com/.
About Nasdaq
Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.
The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq’s proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
Media Contact: | Camille Stafford, Nasdaq | |
Issuer & Investor Contact: | Index Client Services, Nasdaq | |
This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$74.19 |
Daily Change: | -1.03 -1.37 |
Daily Volume: | 378,142 |
Market Cap: | US$33.870B |
July 24, 2025 June 23, 2025 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load